By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panelists agreed that AbbVie's oncology pipeline holds promise for diversifying revenue and offsetting Humira's decline, but they expressed caution about the timeline and risks involved in converting this potential into sustained cash flow and dividend coverage.
Risk: The 2-3 year squeeze on dividend coverage before oncology revenue scales, due to Inflation Reduction Act price cuts and formulary pressure from GLP-1 drugs.
Opportunity: The potential for AbbVie's oncology pipeline to drive approvals and premium pricing, expanding label indications and becoming a primary growth pillar.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
AbbVie (NYSE: ABBV) boasts a pretty attractive dividend at more than 3%.
That's significantly higher than many other blue-chip healthcare stocks, including Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), and Amgen (NASDAQ: AMGN), all of which yield dividends of roughly 2% or less.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
But dividends don't increase just because management wants them to. They rise because the business generates enough cash to support them.
This week, AbbVie presented new data from its blood cancer portfolio at the European Hematology Association (EHA) Congress.
This is one of the world's largest medical conferences focused on blood cancers and disorders, bringing together thousands of physicians, researchers, pharmaceutical companies, and healthcare professionals to present new clinical trial data and discuss emerging treatments.
The reason EHA is important is that companies often use the conference to release new data on cancer drugs, particularly therapies targeting blood cancers. Positive results presented at EHA can support regulatory approvals, label expansions, partnerships, and future revenue growth. That's why AbbVie showcased its new clinical results there.
The company's most recent presentations included data on approved therapies as well as several pipeline candidates. In total, AbbVie showcased 21 presentations spanning multiple blood cancers, including chronic lymphocytic leukemia, follicular lymphoma, multiple myeloma, acute myeloid leukemia, and diffuse large B-cell lymphoma.
AbbVie generated about $61 billion in revenue during 2025, and while immunology drugs receive most of the attention, oncology remains an important contributor.
The company's oncology portfolio generated about $6.7 billion in revenue in 2025. That's not insignificant.
That revenue helps fund research and development, debt reduction, share repurchases, and dividends.
Indeed, oncology helps diversify AbbVie's business.
You may remember the company's dependence on Humira.
At its peak, Humira was one of the best-selling drugs in pharmaceutical history, generating about $21 billion in annual revenue.
That concentration created a significant risk because patents eventually expire. And when Humira lost U.S. exclusivity in 2023, and biosimilar generics entered the market, Humira revenue began declining rapidly.
Management saw this challenge coming years in advance and responded by aggressively building new growth platforms across immunology, oncology, and neuroscience.
Today, drugs such as Skyrizi and Rinvoq (used to treat Crohn's disease, ulcerative colitis, and arthritis) are helping offset Humira's decline, while the company's oncology portfolio provides another important source of revenue and cash flow. The result is a much more diversified business than just a few years ago.
Today, AbbVie generates revenue across immunology, neuroscience, and oncology. That has reduced dependence on any single product and created a more resilient cash flow profile.
And that's why the EHA presentations are relevant.
AbbVie is actively expanding the use of existing drugs while advancing newer therapies that could eventually offset declines from older products. The company highlighted encouraging efficacy data across multiple studies, including late-stage programs and investigational treatments targeting difficult-to-treat blood cancers.
Of course, you can't guarantee successful drug development.
Clinical setbacks happen, and not every program succeeds. It's just part of the overall process of developing new therapies.
Still, AbbVie's oncology portfolio is no longer dependent on a single drug. The company now has multiple approved products, several late-stage opportunities, and a broader pipeline than it did just a few years ago.
Now consider that the latest clinical updates will strengthen the revenue engine supporting the dividend over the long term.
AbbVie's oncology business already generates billions of dollars annually, and management continues working to ensure that oncology remains a growth driver rather than a mature business.
That's why the company continues investing heavily in expanding existing therapies into new indications while advancing next-generation treatments for blood cancers and solid tumors.
Every successful clinical trial creates the potential for new approvals, larger patient populations, and longer revenue runways. And because cancer treatments often command premium pricing and can remain on the market for many years, successful oncology drugs can become meaningful cash-generating assets.
And ultimately, it's cash flow that pays dividends.
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $442,220! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,230,114!
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 12, 2026. *
Jeff Siegel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Amgen, and Eli Lilly. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"EHA updates offer incremental oncology diversification but fall short of transforming AbbVie's cash flow profile enough to guarantee accelerated dividend growth."
AbbVie's 21 EHA presentations on blood cancer therapies could expand label indications for its $6.7B oncology segment within a $61B revenue base, aiding diversification beyond Humira's post-2023 decline and supporting the 3%+ dividend via steadier cash flows. Skyrizi and Rinvoq already offset much of the legacy erosion, but oncology's share remains modest at ~11%. Positive late-stage data may drive approvals and premium pricing, yet conversion to sustained revenue takes years and faces competition. The article downplays execution risk and notes 10 superior picks, tempering immediate upside.
Even encouraging EHA readouts often fail Phase 3 endpoints or face FDA delays, inflating R&D spend without near-term cash flow and eroding margins needed for dividend hikes amid broader patent and reimbursement pressures.
"AbbVie's dividend trajectory hinges on durable free cash flow from a diversified portfolio, but ongoing pipeline risk and pricing pressure could cap growth and threaten long-run dividend expansion."
AbbVie’s note of diversified growth and a dividend yield above 3% sounds constructive, but the bullish script glosses over delivery risk. Humira still fades in biosimilar years; pipeline success is not assured, and late-stage oncology programs can stall or face pricing hurdles. Even if data are encouraging at EHA, regulatory approvals, label expansions, and payer acceptance are binary outcomes with long lead times; cash flow might not scale as fast as dividend commitments imply. The company’s revenue mix remains swingy: oncology is meaningful but still a smaller slice; a sharper pullback in immunology/cancer pricing or higher R&D spend could damp free cash flow and cap dividend growth. Also, valuation multiples matter.
The strongest counterpoint is that even with a slower pipeline, AbbVie already has durable cash flow from Skyrizi and Rinvoq plus Humira tail revenue, which could keep the dividend covered even if late-stage assets stall. In other words, the upside from new indications may be smaller than the article implies, while pricing pressure and biosimilar competition remain real risks.
"AbbVie's dividend sustainability hinges less on clinical trial headlines and more on whether their immunology growth engines can sustain margins while the oncology portfolio scales to replace lost Humira revenue."
AbbVie (ABBV) is currently priced as a value-oriented dividend play, but the market is clearly skeptical of its long-term growth trajectory post-Humira. While the EHA data reinforces the oncology pipeline, investors must recognize that oncology is a 'show-me' story for AbbVie. The company is trading at roughly 14x forward earnings, which is reasonable, but the reliance on Skyrizi and Rinvoq to bridge the massive revenue gap left by Humira creates a high-stakes execution environment. If these immunology blockbusters face unexpected competitive pressure or pricing headwinds, the dividend yield will look less like a value proposition and more like a yield trap. The path to a re-rating depends entirely on whether oncology can move from a 'contributor' to a primary growth pillar.
The oncology portfolio is a 'treadmill' business where massive R&D spend is required just to maintain market share against aggressive biosimilar and novel therapy entrants, potentially cannibalizing the very cash flow intended for dividends.
"AbbVie's dividend is sustainable on current cash flows, but the article's optimism about oncology funding future increases conflates pipeline volume with pipeline value—a common pharma marketing mistake."
The article conflates clinical optionality with cash flow certainty. Yes, 21 EHA presentations signal a diversified oncology pipeline—that's real. But AbbVie's oncology revenue ($6.7B of $61B total) is still dwarfed by immunology, and the article never quantifies: (1) how many of these programs will actually reach approval, (2) peak sales assumptions for each, or (3) timeline to offset Humira's $21B cliff. The 3.3% yield is attractive, but it's pricing in current cash generation, not speculative pipeline wins. Skyrizi and Rinvoq are real offsets, but the article doesn't address competitive pressure from Eli Lilly's GLP-1 franchise cannibalizing immunology indications.
Most of these 21 presentations are likely incremental label expansions or Phase 2 data—not transformative. Clinical trial success rates in oncology remain ~10% from Phase 1 to approval; the article treats pipeline breadth as a proxy for revenue growth without acknowledging attrition risk or the 5-7 year lag before a late-stage program generates material revenue.
"IRA price negotiations pose a nearer-term cash flow threat than speculative GLP-1 overlap."
Claude's claim that Eli Lilly GLP-1s will cannibalize AbbVie's immunology franchise lacks grounding; those assets target metabolic disease, not the IL-23 or JAK pathways Skyrizi and Rinvoq address. A clearer unmentioned risk is the Inflation Reduction Act's Medicare negotiation timeline, which could force 2026 price cuts on Rinvoq before oncology data convert to meaningful revenue, pressuring the 3.3% yield coverage.
"IRA price cuts are a risk, but AbbVie's dividend safety will hinge more on pipeline execution and payer dynamics than on 2026 price reforms alone."
To Grok: The IRA angle is a valid warning, yet framing it as the dominant near-term risk may overstate the impact on AbbVie's cash flow. Price concessions in 2026 depend on negotiation dynamics and product competition, not a certainty. The bigger swing factor remains whether the oncology bets translate into material, growing revenue, and whether payer acceptance keeps Skyrizi/Rinvoq margins intact amid ongoing biosimilar and label-expansion pressure. Yield is still a function of multiple moving parts beyond IRA.
"Increased GLP-1 spending will force PBMs to demand higher rebates on immunology blockbusters, compressing AbbVie's margins."
Grok, your dismissal of GLP-1 cross-category impact is premature. While the mechanisms differ, the 'share of wallet' for immunology spend is finite. If payers prioritize GLP-1s for systemic inflammation or obesity-related comorbidities, they will squeeze the formulary space for high-cost biologics like Skyrizi. The real risk isn't direct competition, but a systemic shift in pharmacy benefit manager (PBM) leverage that forces deeper rebates across all high-cost specialty drugs, regardless of the specific biological pathway.
"AbbVie's dividend faces a near-term cash flow pinch (IRA + PBM pressure) before oncology pipeline can offset it, creating a 2-3 year coverage vulnerability."
Gemini's 'share of wallet' argument is sharper than Grok's mechanism dismissal, but both miss the timing mismatch. GLP-1 formulary pressure is real and accelerating now; AbbVie's oncology revenue inflection is 3-5 years out. The IRA price cuts hit Rinvoq in 2026 before oncology scales. So the yield faces a 2-3 year squeeze before pipeline upside materializes. That's the actual risk: not whether oncology works, but whether dividend coverage survives the interim.
The panelists agreed that AbbVie's oncology pipeline holds promise for diversifying revenue and offsetting Humira's decline, but they expressed caution about the timeline and risks involved in converting this potential into sustained cash flow and dividend coverage.
The potential for AbbVie's oncology pipeline to drive approvals and premium pricing, expanding label indications and becoming a primary growth pillar.
The 2-3 year squeeze on dividend coverage before oncology revenue scales, due to Inflation Reduction Act price cuts and formulary pressure from GLP-1 drugs.